<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719745</url>
  </required_header>
  <id_info>
    <org_study_id>MR-05-02-KOR</org_study_id>
    <nct_id>NCT00719745</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of Prograf and MR4 in Liver Transplant Recipients</brief_title>
  <official_title>A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of PrografÂ® (Tacrolimus) and MR4 (Modified Release Tacrolimus) in de Novo Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate and to compare efficacy and safety of MR4 versus Prograf in patients undergoing
      primary liver transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event rate of patients with biopsy-proven acute rejections</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of and time to acute rejections and corticosteroid resistant acute rejections</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of biopsy-proven acute rejections.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Throughout trial</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>oral</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Tacrolimus</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MR4</intervention_name>
    <description>oral</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Modified Release Tacrolimus</other_name>
    <other_name>FK506MR</other_name>
    <other_name>FK506E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients of child bearing potential must have a negative in pregnancy test
             prior to enrollment and must agree to practice effective birth control during the
             study

          -  Patients who need liver transplantation due to the end-stage liver failure

        Exclusion Criteria:

          -  Patients receiving multi-organ transplant or having previously received an organ
             transplant ( including re-transplantation)

          -  Patients receiving auxiliary graft or in whom a bio-artificial

          -  Patients allergic to macrolide antibiotics or tacrolimus

          -  Patients requiring immunosuppressive treatment or systemic chemotherapy prior to
             transplantation. Patients requiring low level immunosuppressive treatment ( MMF,
             steroids, azathioprine ) before transplantation to control their original liver
             disease can be included in the study, provided that this treatment is discontinued at
             the time of transplantation. Local chemotherapy is allowed

          -  Patients with malignancies of a history of malignancy within the last 5 years, with
             the exception of those with basalioma or squamous cell carcinoma of the skin that has
             been treated successfully Patients can be included under Milan Criteria Patients with
             malignancy which was identified after completion of surgery e.g. by histopathology
             will be allowed to remain in the study

          -  Patients with systemic infection requiring treatment, except viral hepatitis

          -  Patients with severe diarrhea, vomiting, active peptic ulcer or gastrointestinal
             disorder that may affect the absorption of tacrolimus

          -  Patients with serum creatinine &gt; 1.5mg/Dl

          -  Patients with any form of substance abuse, psychiatric disorder of condition which, in
             the opinion of the investigator, may complicate communication with the investigator

          -  Patients participating or participated in another clinical trial or those taking or
             having taken an investigational / non-registered drug in the past 28 days

          -  Patients who are pregnant or breast-feeding mother

          -  Patients or donors known to be HIV positive

          -  Patients unlikely to comply with the visits scheduled in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Korea, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2008</study_first_submitted>
  <study_first_submitted_qc>July 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <last_update_submitted>July 18, 2008</last_update_submitted>
  <last_update_submitted_qc>July 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director</name_title>
    <organization>Astellas Pharma Inc.</organization>
  </responsible_party>
  <keyword>Organ transplantation</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Prograf</keyword>
  <keyword>MR4</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

